Prescription Practices of Medical Cannabinoids in Children with Cerebral Palsy - A Survey of the Swiss Cerebral Palsy Registry
Aim Medical cannabinoids are prescribed to children with cerebral palsy despite limited evidence. We aimed to assess the prescription practices of cannabinoids in children with cerebral palsy with a particular focus on indications and preparations used and how well cannabinoids are tolerated. Furthermore, we investigated how physicians acquire knowledge on cannabinoid medication. Methods We asked physicians with expertise in the care of children with CP on their prescription practices of medical cannabinoids. Data was collected through an online survey, which was distributed by email. In addition to the demographic information of participants, we also inquired about the indications for the prescription of cannabinoids, about experiences regarding efficacy and the observed side effects of the therapy. Results Seventy physicians from Europe, North America and Australia completed the survey. Forty-seven participants were experienced in the treatment of children with cerebral palsy by cannabinoids. The most common indication was epilepsy (69%), followed by spasticity (64%) and pain (63%). The prescribed preparations and doses varied considerably. Half of the participants evaluated the effect of the medical cannabinoids as moderate. Twenty-nine physicians reported side effects, most frequently in the form of drowsiness (26%), somnolence (19%), fatigue (13%), and diarrhoea (13%). Conclusions Despite the lack of evidence to date, medical cannabinoids are used to treat children with cerebral palsy in a wide variety of indications. Randomized controlled trials in this vulnerable patient group are therefore of utmost importance.